Effect of augmented renal clearance on plasma concentration of vancomycin and treatment outcome in children with methicillin-resistant Staphylococcus aureus infection.
- Author:
Cui-Yao HE
1
;
Yan-Ran QIN
;
Cheng-Jun LIU
;
Jie REN
;
Ji-Shan FAN
Author Information
1. Department of Pharmacy, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/National Clinical Research Center for Child Health and Disorders (Chongqing)/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.liucwd@163.com.
- Publication Type:Journal Article
- MeSH:
Anti-Bacterial Agents;
Child;
Child, Preschool;
Humans;
Infant;
Methicillin;
Methicillin-Resistant Staphylococcus aureus;
Retrospective Studies;
Staphylococcal Infections;
drug therapy;
Treatment Outcome;
Vancomycin;
therapeutic use
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(9):904-909
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of augmented renal clearance (ARC) on plasma concentration of vancomycin, bacteriological outcome, and clinical outcome in children with methicillin-resistant Staphylococcus aureus (MRSA) infection treated by vancomycin.
METHODS:A retrospective analysis was performed for the clinical data of 60 critically ill children who were treated with vancomycin due to MRSA infection from January 2013 to July 2017 and underwent plasma concentration monitoring. According to estimated glomerular filtration rate, these children were divided into an ARC group with 19 children and a normal renal function group with 41 children. The two groups were compared in terms of the use of vancomycin, plasma concentration of vancomycin, and treatment outcome.
RESULTS:The children in the ARC group had an age of 1-12 years, and the ARC group had significantly higher body weight and body surface area than the normal renal function group (P<0.05). Compared with the normal renal function group, the ARC group had a significantly lower initial trough concentration of vancomycin and a significantly lower proportion of children who achieved the effective trough concentration of vancomycin (10-20 mg/L) (P<0.05). There were no significant differences in bacteriological outcome and clinical outcome between the two groups (P>0.05), but the ARC group had significantly longer length of stay in the pediatric intensive care unit (PICU) and length of hospital stay than the normal renal function group (P<0.05).
CONCLUSIONS:ARC can significantly reduce the trough concentration of vancomycin and prolong the length of PICU stay and the length of hospital stay in children with MRSA infection. Idividualized medication should be administered to children with ARC.
